The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a cross-sectional survey to explore determinants of health-promoting activities among Hispanic/Latino (H/L) patients (pts) with prostate cancer (PCa) on androgen deprivation therapy (ADT).
 
Sharon Choi
No Relationships to Disclose
 
Frances Ramos Diaz
No Relationships to Disclose
 
Kristine Ly
No Relationships to Disclose
 
Yu-Wei Chen
Employment - Amgen (I)
Stock and Other Ownership Interests - Amgen (I)
Honoraria - Eisai; Janssen; OncLive/MJH Life Sciences
Consulting or Advisory Role - Eisai
Travel, Accommodations, Expenses - DAVA Oncology
 
James Randall
No Relationships to Disclose
 
Tyler Stewart
Consulting or Advisory Role - AstraZeneca; Seattle Genetics/Astellas
Research Funding - GRAIL
 
Fred Millard
No Relationships to Disclose
 
James Murphy
No Relationships to Disclose
 
Noe Crespo
No Relationships to Disclose
 
Soo Park
Consulting or Advisory Role - Regeneron
Research Funding - BMS (Inst); Incyte (Inst); Merck (Inst); Regeneron (Inst)
 
Brent Rose
Employment - UC San Diego Health
 
Aditya Bagrodia
Consulting or Advisory Role - Ferring; Veracyte
 
Elena Martinez
No Relationships to Disclose
 
Rana McKay
Consulting or Advisory Role - Ambrx; Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)